Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

437.15 +2.63 (+0.61%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
68 69 Next >
News headline image
2 Healthcare Stocks You Can Buy Right Now Before They Surge Even Higher ↗
Via The Motley Fool
News headline image
MaxCyte: Building the Future of Cell and Gene Therapy Innovation
MaxCyte's proprietary Flow Electroporation technology enables companies like Vertex and CRISPR Therapeutics to get FDA approved for their gene-editing therapy. 
Via MarketBeat
News headline image
Got $1,500? 3 Healthcare Stocks to Buy and Hold Forever ↗
Via The Motley Fool
News headline image
8 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
3 Unstoppable Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
How Is The Market Feeling About Vertex Pharmaceuticals? ↗
 
Via Benzinga
News headline image
Forecasting The Future: 23 Analyst Projections For Vertex Pharmaceuticals ↗
 
Via Benzinga
News headline image
If You Invested $1000 In This Stock 20 Years Ago, You Would Have This Much Today ↗
 
Via Benzinga
News headline image
HHS Challenges Vertex Over Fertility Services Program Tied To Casgevy Gene Therapy, Says Company Is 'Grasping at Straws' ↗
HHS challenges Vertex Pharmaceuticals' fertility services program, alleging violations of anti-kickback laws linked to its gene-editing therapy for sickle cell disease. 
Via Benzinga
News headline image
Vertex's Pain Drug: Big Pharma's Next Major Success?
Vertex Pharmaceuticals' innovative pain drug holds significant potential, positioning the company for substantial growth in the expanding market. 
Via MarketBeat
News headline image
Should You Buy Vertex Pharmaceuticals Stock Hand Over Fist Before Jan. 30? ↗
Via The Motley Fool
News headline image
Here's How Much $100 Invested In Vertex Pharmaceuticals 10 Years Ago Would Be Worth Today ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Sets Sight on Expanding Portfolio with Alyftrek Approval, Pain Treatment Progress, and Diabetes Trials ↗
Vertex secures FDA approval for ALYFTREK and expands TRIKAFTA use, advances diabetes and kidney disease therapies, and strengthens its global drug pipeline. 
Via Benzinga
News headline image
Meet the Innovative Growth Stock That Could Rocket 114% to 152% Higher in 2025, According to a Couple of Wall Street Analysts ↗
Via The Motley Fool
News headline image
My 3 Highest-Conviction Growth Stocks to Buy in 2025 ↗
Via The Motley Fool
News headline image
Vertex Provides Pipeline and Business Updates in Advance of Upcoming Investor Meetings
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Pfizer Is 'Too Low To Sell,' Jim Cramer Says: Recommends Nvidia For Robotics Exposure ↗
Pfizer stock is down more than 7% over the past year. The pharma giant is in talks to extend its collaboration with an AI start-up. 
Via Benzinga
Topics Artificial Intelligence
News headline image
Vertex and Zai Lab Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan Region and Singapore
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Zai Lab and Vertex Announce Strategic Agreement to Develop and Commercialize Povetacicept in Mainland China, Hong Kong SAR, Macau SAR, Taiwan region and Singapore
From Zai Lab Limited
Via Business Wire
News headline image
Biotech Stocks Prepare For Action In 2025. Weight-Loss Drugs, AI And Trump 2.0 Are The Catalysts. ↗
Biotech stocks have seen three years of sideways to down trading. But obesity drugs, AI and Trump 2.0 promise to shake things up. 
Via Investor's Business Daily
Topics Artificial Intelligence Government
News headline image
Vertex Grapples With Bearish Chart As Death Cross Emerges ↗
Vertex Pharmaceuticals (VRTX) is facing technical challenges, with its stock forming a Death Cross and down 15% in 6 months. 
Via Benzinga
News headline image
2 Gene-Editing Stocks Positioned for a Strong Comeback in 2025
Gene editing is a reality and it has potential to cure hereditary diseases in a single treatment. These 2 stocks are pioneers in the CRISPR/Cas-9 space. 
Via MarketBeat
News headline image
Why This Beaten-Down Growth Stock Is a No-Brainer Buy on the Dip ↗
Via The Motley Fool
News headline image
10 Health Care Stocks With Whale Alerts In Today's Session ↗
 
Via Benzinga
News headline image
Vertex Pharmaceuticals Stock Is Down 13%. Here's Why You Should Buy the Dip ↗
Via The Motley Fool
News headline image
Top Stock Reports For T-Mobile, Toyota Motor & Vertex Pharmaceuticals ↗
Today's Research Daily features new research reports on 16 major stocks, including T-Mobile US, Inc., Toyota Motor Corp., and Vertex Pharmaceuticals Inc., as well as two micro-cap stocks BK... 
Via Talk Markets
Topics Stocks / Equities
News headline image
3 No-Brainer Stocks to Buy on the Latest Sell-Off ↗
Via The Motley Fool
News headline image
Vertex to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 13
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Pharmaceuticals: Alyftrek Is An 'Accretive Opportunity' On Top- And Bottom-Lines, Says Bullish Analyst ↗
Vertex Pharmaceuticals announced FDA approval for Alyftrek, which expands the company's CF franchise to address around 6,000 such patients. 
Via Benzinga
News headline image
Microsoft To Rally Around 26%? Here Are 10 Top Analyst Forecasts For Monday ↗
 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 17
...
68 69 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.